IACS-010759

IACS-010759 is an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 inhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 has the potential for relapsed/refractory AML and solid tumors research[1][2].

Product Specifications

CAS Number

[1570496-34-2]

Product Name Alternative

IACS-10759

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Mitochondrial Metabolism; Oxidative Phosphorylation

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/IACS-10759.html

Purity

99.68

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

FC(F)(F)OC1=CC=C(C2=NOC(C3=NN(CC4=CC(N5CCC(S(=O)(C)=O)CC5)=CC=C4)C(C)=N3)=N2)C=C1

Molecular Formula

C25H25F3N6O4S

Molecular Weight

562.56

Precautions

H302, H315, H319, H335

References & Citations

[1]Protopopova M. IACS-10759: A novel OXPHOS inhibitor which selectively kill tumors with metabolic vulnerabilities. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA) : AACR; Cancer Res 2015;75 (15 Suppl) :Abstract nr 4380. doi:10.1158/1538-7445.AM2015-4380|[2]Jennifer R Molina, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018 Jul;24 (7) :1036-1046.